RNS Number:5026R
BioProgress PLC
31 October 2003


Press Release                                                 31 October 2003

                              BioProgress plc

BioProgress announces the signing of a contract with Harro Hoefliger


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, announces today it has executed a formal
contract with Harro Hoefliger GmbH. This follows the execution of a letter of
intent announced in September 2003. The agreement signed today appoints Harro
Hoefliger as the exclusive builder, supplier and service and warranty provider
for all BioProgress TABWRAP(R), SWALLOW, SEPTUM(R) and NROBE(R) machines. The
agreement provides for BioProgress to receive revenues from machine sales and a
royalty on all revenues generated by Harro Hoefliger from machine service
activities.


Alan Holmes of Harro Hoefliger, said:  "Since we signed the letter of intent the
production teams at Harro Hoefliger and BioProgress have been working closely
together to agree detailed project plans, machine specifications, costs and
delivery timeframes.  Harro Hoefliger is delighted to be entering into a long
term commercial partnership with BioProgress to develop this exciting
technology."


Graham Hind, Chief Executive Officer of BioProgress, said:  "The agreement with
Harro Hoefliger has been extremely well received by our customers and strategic
partners. It is an important milestone for BioProgress to secure a partnership
with a world class, well respected, global machine supplier to the
pharmaceutical industry. Not only does this give confidence to our existing
customers it significantly enhances our capability to win new customers and
exploit opportunities in additional areas of the world where this agreement with
Harro Hoefliger now enables us to operate."

                                 - Ends -



For further information:
BioProgress plc
Graham Hind, Chief Executive                           Tel: +44 (0) 1354 655 674
grahamhind@bioprogress.com                                   www.bioprogress.com


Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond                Tel: +44 (0) 20 7444 4140
henry.ht@bankside.com                                           www.bankside.com


Notes to editors:

BioProgress listed on AIM in May 2003 and is engaged in the research,
development, and design of patented encapsulation systems that use water soluble
and biodegradable films for the dietary supplement, pharmaceutical and other
sectors. The Company's patent portfolio comprises over sixty patents within
sixteen patent families and has product development agreements and strategic
alliances with several global companies.  BioProgress aims to provide a cost
effective and animal-free encapsulation process for pharmaceutical drugs in
liquids, tablets and powders, thereby addressing the needs of the entire market
for oral dosage forms while providing novel delivery mechanisms not possible
with traditional processes.


The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user. Market research shows the global ostomy market to be
worth $1 billion annually.


The Company's business model provides it with several significant revenue
streams including sales of encapsulating machines and film, plus licence and
fees for research development services.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

CNTEASEEDDNDFFE